Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.

View in: PubMed

subject areas

Adult
Amenorrhea
Antineoplastic Combined Chemotherapy Protocols
Breast Neoplasms
Female
Humans
Maytansine
Middle Aged
Paclitaxel
Receptor, ErbB-2
Trastuzumab
Young Adult

authors with profiles

Rita Nanda